J&J Exits RSV Race After Competing Shots Advance Toward Approval

Johnson & Johnson halted development of a vaccine for respiratory syncytial virus infections in adults, leaving a $10 billion market to competitors who are ahead in their efforts.

J&J decided to discontinue its program after assessing the RSV vaccine landscape, the company said. The decision isn’t a surprise to analysts, who said safety concerns over J&J’s vaccine platform appeared to slow recruitment for clinical trials and might limit its use in the market.

Wall Street had estimated J&J could generate sales of $975 million by 2028, Bloomberg Intelligence analyst John Murphy said Wednesday in a note, calling the announcement ...